AMRI New Mexico facility approved for BARDA network

The network is part of a US government initiative to improve preparedness capabilities

Albany Molecular Research, (AMRI), today announced its Albuquerque, New Mexico, facility has been approved for inclusion in the Biomedical Advanced Research and Development Authority (BARDA) CDMO network.

AMRI’s Albuquerque location includes a large-scale fill and finish facility, currently supporting COVID-19 vaccine production. Inclusion in the network reportedly recognises AMRI’s pandemic preparedness, its existing support of COVID-19 vaccine production, experience in government contracting and its ability to support further BARDA contract work at Albuquerque.

“We are proud to join the BARDA CDMO network, reflecting our commitment to play a vital role in the COVID-19 pandemic response,” said John Ratliff, CEO, AMRI. “AMRI’s track record of navigating complex environments, based on our broad capabilities from R&D through manufacturing, enables us to contribute to this critical moment in improving health.”

Sites included in BARDA’s CDMO network are vetted and prequalified for the immediate production of medical countermeasures in the event of a health threat in the US. BARDA is overseen by the Health and Human Services Assistant Secretary for Preparedness and Response.

Companies